Leukemia Research
Volume 28, Issue 8 , Pages 845-850 , August 2004

Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis

  • Todd W Kelley

      Affiliations

    • Department of Clinical Pathology, L11, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, USA
    • ,
  • Serhan Alkan

      Affiliations

    • Department of Pathology, Loyola University Medical Center, Maywood, IL, USA
    • ,
  • Gordan Srkalovic

      Affiliations

    • Department of Hematology and Medical Oncology and Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH, USA
    • ,
  • Eric D Hsi

      Affiliations

    • Department of Clinical Pathology, L11, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-216-444-5230; fax: +1-216-444-4414.

Received 12 September 2003 ,Accepted 3 December 2003.

References 

  1. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840–1847
  2. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymnphocytic leukemia. Blood. 1999;94:1848–1854
  3. Garg A, Aggarwal BB. Nuclear transcription factor-kappa B as a target for cancer drug development. Leukemia. 2002;16:1053–1068
  4. Furman R, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia cells. J. Immunol. 2000;164:2200–2206
  5. Chen C, Edelstein LC, Gelinas C. The Rel/NF-B family directly activates expression of the apoptosis inhibitor Bcl-xL. Mol. Cell. Biol. 2000;20:2687–2695
  6. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS. NF-kappa B controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 1999;19:5785–5799
  7. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, et al.  Proteasome inhibitor PS-341 inhibits myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002;62:4996–5000
  8. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, et al.  The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101:2377–2380
  9. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al.  A phase II study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003;348:2609–2617
  10. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, et al.  A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 2002;8:2505–2511
  11. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, et al.  Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 2002;20:4420–4427
  12. Almond JB, Snowden RT, Hunter A, Dinsdale D, Cain K, Cohen GM. Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700kDa Apaf1-containing apoptosome complex. Leukemia. 2001;15:1388–1397
  13. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al.  ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N. Engl. J. Med. 2003;348:1764–1775

PII: S0145-2126(03)00418-1

doi: 10.1016/j.leukres.2003.12.010

Leukemia Research
Volume 28, Issue 8 , Pages 845-850 , August 2004

Article Tools

* Image Usage & Resolution